Reviewer's report

Title: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer [ISRCTN13413322]

Version: 2 Date: 10 June 2006

Reviewer: Henry Q Xiong

Reviewer's report:

General
I have no additional comments

-------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

-------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

-------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

-------------------------------------------------------------------------------

What next?: Accept without revision

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes

Declaration of competing interests:
I declare that I have no competing interests